Skip Navigation
News and Publications
 
 
 
In This Section      
Print This Page

Bert Vogelstein, M.D., Awarded Breakthrough Prize in Life Sciences

Has made seminal contributions to cancer genetics 

Dr. Bert Vogelstein

Bert Vogelstein, M.D., co-director of the Ludwig Center at Johns Hopkins, Clayton Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center, and a Howard Hughes Medical Institute investigator, has been awarded the Breakthrough Prize in Life Sciences.

The prize was created by Sergey Brin and Anne Wojcicki, Mark Zuckerburg and Priscilla Chan and Yuri Milner to reward scientists working to cure disease and extend human life. Each of the 11 winners will recieve $3 million. This is the first year the prize has been awarded.

Vogelstein graduated from the Johns Hopkins School of Medicine in 1974 and began studying pediatrics at The Johns Hopkins Hospital. Seeing young children suffering from cancer spurred his interest in the disease. He spent two years at the National Cancer Institute before returning to Johns Hopkins in 1978 to direct the cancer center's molecular genetics laboratory.

In summarizing his discoveries of the last 30 years, Vogelstein says, "Cancer is, in essence, a genetic disease." But more than 20 years ago when Vogelstein first cracked open the Pandora's Box that is cancer, revealing first one and then a series of genetic mistakes responsible for colon cancer, a link between genetics and cancer was a foreign concept. Today, his discoveries continue to lead his lab and others around the world in developing genetic tests, diagnostics and therapies for cancer.

In 1989, Vogelstein's identification of p53 gene mutations in colon cancer began a tide of research linking alterations in the gene to other cancers. It is now known as the most common gene mutation in all cancers. Vogelstein's lab then discovered a series of other mutations linked to p53. The difficulty of these discoveries is akin to finding one typographical error within 20 volumes of an encyclopedia, and then figuring out how it got there.

As a result of his findings, Vogelstein was ranked in 2003 as the most highly-cited scientist in the world during the previous 20 years, according to the Institute for Scientific Information in Philadelphia.

Vogelstein and his colleagues created gene tests for some rare forms of hereditary colon cancers, and later, created a stool test to screen for genes linked to more common, sporadic colon cancers.

More recently, Vogelstein and his colleagues were the first to create genomic maps of cancer starting with breast and colon cancers. They've mapped scores of other cancer genes, leading to the discovery of mutations in the IDH1 gene, which are common in brain cancer.

With new, faster computing tools to sequence cancer DNA, Vogelstein's team completed 88 of the first 100 whole exomic (that is, all the genes in the genome) sequences of human cancers. These detailed maps create guides scientists can use to pinpoint characteristics of each person's cancer and tailor therapies and diagnostics to guide treatment, and represent an important step toward personalized medicine.

Additional Resources

Related Articles and Press Releases

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer